Bayer invests $215m as Century advances cell therapy programs 09-Jul-2019 By Maggie Lynch Century Therapeutics advances its allogeneic cell therapy platform created programs to the clinic after a $250m in financing led by Bayer.
Cellectis to build CAR-T manufacturing sites in US and Europe 14-Mar-2019 By Ben Hargreaves In a step towards the commercialisation of its ‘off-the-shelf’ CAR-T therapies, Cellectis begins construction of a facility in France and enters lease agreement for US facility.
Allogene builds allogeneic CAR-T site, looking ahead to ‘commercial product’ 27-Feb-2019 By Ben Hargreaves Allogene enters a lease agreement to develop a 118,000-square-foot site for the manufacture of allogeneic CAR-T therapies.
